Enzalutamide Plus ADT Yields Lasting Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer ± Prior Therapy
May 21, 2022

Findings from the phase 3 ARCHES trial highlighted a long-lasting survival improvement for patients with metastatic hormone-sensitive prostate cancer who were treated with enzalutamide plus androgen deprivation therapy regardless of whether they received prior local therapy.

Neoadjuvant Atezolizumab Yields High DFS in Muscle-Invasive Urothelial Cancer
May 21, 2022

Neoadjuvant atezolizumab as a treatment for muscle-invasive urothelial cancer of the bladder yielded a high disease-free survival.

FDA Approved Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukemia
May 20, 2022

Based on the results of the AZA-JMML-001 trial, the FDA has approved azacitidine for use in newly diagnosed juvenile myelomonocytic leukemia.

First-Line Lenvatinib Plus Pembrolizumab Yields Comparable in HRQOL Vs Sunitinib for Advanced RCC
May 20, 2022

Patients with advanced renal cell carcinoma who were treated with lenvatinib plus pembrolizumab had health-related quality of life comparable with sunitinib.

Switch Maintenance Endocrine Therapy With Bevacizumab Shows Promise in ER+ HER2– Advanced Breast Cancer
May 20, 2022

Patients with estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer may receive alternative treatment with switch maintenance endocrine therapy and bevacizumab and experience notable efficacy and improved safety vs continued weekly paclitaxel and bevacizumab.

Recap: A Review of Multiple Myeloma Trials That Impact the Standard of Care
May 20, 2022

A panel of experts provides a discussion on treatments for newly diagnosed transplant-eligible and transplant-ineligible relapsed multiple myeloma, and how recent clinical trial data presented at ASH 2021 can be applied to clinical practice.

Patient Profile 2: EGFR Exon 19 Deletion–Positive NSCLC
May 20, 2022

Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.

NSCLC: Selecting Therapy Based on PD-L1 Status and Staging
May 20, 2022

A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.

Isatuximab Plus Kd Yields Consistent PFS Benefit Vs Kd Alone in Relapsed Multiple Myeloma
May 20, 2022

Updated results from the phase 3 IKEMA study showed a progression-free survival benefit with the addition of isatuximab to carfilzomib and dexamethasone that was consistent with interim results in patients with relapsed multiple myeloma.

Mark T. Fleming, MD, Talks Use of 18F-rhPSMA-7.3 for PET/CT in Recurrent Prostate Cancer
May 19, 2022

Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.